You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Deriving Bone Density from Thoracic CT Scans

    SBC: BDI, Inc.            Topic: NIAMS

    PROJECT SUMMARY ABSTRACT As people age they steadily lose bone mass and their bones become fragile and increasingly prone to hip and other fractures and this can prove fatal The American College of Radiology therefore recommends that assessment of bone mineral density BMD be performed in post menopausal women and all people over the age of every two years If indicated preventive measure ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring

    SBC: ODMR Technologies, Inc            Topic: 400

    DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases

    SBC: Azitra Inc.            Topic: NIAID

    PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Genotype-linked Antibiotic Resistance Platform for Real Time Pathogen Risk Classification and Epidemiology

    SBC: MAVERIX BIOMICS, INC.            Topic: NIAID

    Project Summary Antibiotic resistance has become a pressing public health concern due to the rise of pathogenic bacterial strains with mutations that reduce or eliminate the effectiveness of drugs to treat infections Beta lactamases produced by some bacteria provide resistance by degrading beta lactams one of most widely used class of antibiotics Originally restricted to penicillins mutant bet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergy

    SBC: ABWIZ BIO INC            Topic: NIAID

    DESCRIPTION provided by applicant The prevalence of food allergy has been dramatically increasing for the last few decades Food Allergy and Anaphylaxis Network www foodallergy org estimates that up to million Americans have food allergies Six to eight percent of children under the age of three have food allergies and nearly four percent of adults have them Signs and symptoms of food all ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. PreImplantation Factor plus hypothermia to treat neonatal brain injury

    SBC: BioIncept, LLC            Topic: NICHD

    ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evide ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government